Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

48.58USD
4:00pm EDT
Price Change (% chg)

$0.41 (+0.85%)
Prev Close
$48.17
Open
$48.47
Day's High
$48.67
Day's Low
$48.04
Volume
4,403,105
Avg. Vol
3,735,007
52-wk High
$50.16
52-wk Low
$40.10

MRK.N

Chart for MRK.N

About

Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceuti... (more)

Overall

Beta: 0.58
Market Cap (Mil.): $145,454.70
Shares Outstanding (Mil.): 3,019.61
Dividend: 0.43
Yield (%): 3.57

Financials

  MRK.N Industry Sector
P/E (TTM): 28.68 37.93 37.76
EPS (TTM): 1.68 -- --
ROI: -- 19.48 18.76
ROE: -- 20.17 19.59
Search Stocks

Cost controls help Pfizer, Merck weather weak quarter

- Big Pharma is still relying on belt-tightening to prop up financial results.

30 Jul 2013

WRAPUP 1-Cost controls help Pfizer, Merck weather weak quarter

July 30 - Big Pharma is still relying on belt-tightening to prop up financial results.

30 Jul 2013

Merck revenues miss mark as diabetes, arthritis drugs lag

- Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia.

30 Jul 2013

UPDATE 2-Merck revenue hit by weak overseas, consumer sales

July 30 - Merck & Co Inc's quarterly revenue fell short of expectations on disappointing results for the company's consumer and animal health products and weak overseas sales of prescription drugs that were slammed by the stronger dollar.

30 Jul 2013

Merck revenue misses mark as diabetes, arthritis drugs lag

July 30 - Merck & Co's quarterly revenue fell short of Wall Street expectations, on lower sales of its consumer health and animal health products and weak growth of its treatments for diabetes and arthritis.

30 Jul 2013

FDA accepts review of long-delayed Merck blood clot drug

July 24 - Merck & Co. on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing heart attacks and strokes in patients who have already had a heart attack but who have no history of stroke.

24 Jul 2013

UPDATE 1-FDA accepts review of long-delayed Merck blood clot drug

July 24 - Merck & Co. on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing heart attacks and strokes in patients who have already had a heart attack but who have no history of stroke.

24 Jul 2013

FDA accepts review of long-delayed Merck blood clot drug

July 24 - Merck & Co on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing heart attacks and strokes in patients who have already had a heart attack but who have no history of stroke.

24 Jul 2013

Merck drug to reverse anesthesia delayed again at FDA

WASHINGTON - U.S. health regulators need more time to review Merck & Co's application to sell sugammadex, an injection designed to reverse the effects of muscle relaxants used during surgery, the company said on Tuesday.

16 Jul 2013

UPDATE 3-Merck drug to reverse anesthesia delayed again at FDA

WASHINGTON, July 16 - U.S. health regulators need more time to review Merck & Co's application to sell sugammadex, an injection designed to reverse the effects of muscle relaxants used during surgery, the company said on Tuesday.

16 Jul 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$58.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$495.00
Provider: Plunkett Research, Ltd.
$99.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks